2026-04-17T00:55:52Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4733992025-09-22T07:13:02Zcom_2072_98col_2072_378192

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : A retrospective analysis of the EBMT chronic malignancies working party Scheid, Christof de Wreede, Liesbeth C Van Biezen, A. Koenecke, C. Göhring, G. Volin, L. Maertens, J. Finke, Juergen Passweg, J. Beelen, Dietrich Cornelissen, J. J. Itälä-Remes, Maija Chevallier, P. Russell, N. Petersen, E. Milpied, N. Richard Espiga, C. Peniket, A. Sierra Llopart, Jordi Mufti, G. Crawley, C. Veelken, J.H. Ljungman, P. Cahn, Jean-Yves Alessandrino, E.P. de Witte, Theo Robin, M. Kröger, N. Universitat Autònoma de Barcelona The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (Po0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (Po0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant. 2017 Article Bone marrow transplantation ; Vol. 52 Núm. 11 (january 2017), p. 1519-1525 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. https://creativecommons.org/licenses/by-nc-nd/4.0/